Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.
SKYSEQ
Show more
Research and development of pharmaceuticals, namely, small molecule therapies for the alteration of RNA splicing and expression, used in the treatment of cancers, neurological diseases, infectious diseases and other diseases using integrated and high-throughput screening technologies coupled with next-generation sequencing
Class 42 – Technology & SaaS
Status timeline
- 23 Mar 2021Application filedNew Application Entered
- 21 Oct 2021Assigned to an examining attorneyAssigned To Examiner
- 26 Apr 2022Response to office action filedTeas Response To Office Action Received
- 1 Jun 2022Approved for publicationApproved For Pub - Principal Register
- 5 Jul 2022Published for oppositionPublished For Opposition
- 30 Aug 2022Notice of allowance issued — statement of use requiredNoa Mailed - Sou Required From Applicant
- 22 Feb 2023Statement-of-use extension 1 grantedSou Extension 1 Granted
- 21 Aug 2023Statement-of-use extension 2 grantedSou Extension 2 Granted
- 19 Feb 2024Statement-of-use extension 3 grantedSou Extension 3 Granted
- 28 May 2024Statement of use filedTeas Statement Of Use Received
- 18 Oct 2024Office action issuedNon-Final Action Written
- 24 Oct 2024Response to office action filedTeas Response To Office Action Received
- 20 Mar 2025Statement of use acceptedAllowed Principal Register - Sou Accepted
- 8 Apr 2025Registered on the Principal RegisterRegistered-Principal Register
All 42 events
| 2025-04-08 | Registered-Principal Register |
| 2025-04-08 | Notice Of Registration Confirmation Emailed |
| 2025-03-20 | Allowed Principal Register - Sou Accepted |
| 2025-03-20 | Notice Of Acceptance Of Statement Of Use E-Mailed |
| 2024-11-01 | Assigned To Lie |
| 2024-11-01 | Correspondence Received In Law Office |
| 2024-11-01 | Teas/Email Correspondence Entered |
| 2024-10-24 | Teas Response To Office Action Received |
| 2024-10-18 | Non-Final Action Written |
| 2024-10-18 | Non-Final Action E-Mailed |
| 2024-10-18 | Notification Of Non-Final Action E-Mailed |
| 2024-08-27 | Sou Teas Extension Received |
| 2024-07-06 | Case Assigned To Intent To Use Paralegal |
| 2024-07-06 | Statement Of Use Processing Complete |
| 2024-05-28 | Teas Statement Of Use Received |
| 2024-05-28 | Use Amendment Filed |
| 2024-02-20 | Notice Of Approval Of Extension Request E-Mailed |
| 2024-02-19 | Sou Teas Extension Received |
| 2024-02-19 | Sou Extension 3 Filed |
| 2024-02-19 | Sou Extension 3 Granted |
| 2023-08-23 | Notice Of Approval Of Extension Request E-Mailed |
| 2023-08-21 | Sou Teas Extension Received |
| 2023-08-21 | Sou Extension 2 Filed |
| 2023-08-21 | Sou Extension 2 Granted |
| 2023-02-24 | Notice Of Approval Of Extension Request E-Mailed |
| 2023-02-22 | Sou Teas Extension Received |
| 2023-02-22 | Sou Extension 1 Filed |
| 2023-02-22 | Sou Extension 1 Granted |
| 2022-08-30 | Noa Mailed - Sou Required From Applicant |
| 2022-07-05 | Published For Opposition |
| 2022-07-05 | Official Gazette Publication Confirmation E-Mailed |
| 2022-06-15 | Notification Of Notice Of Publication E-Mailed |
| 2022-06-01 | Approved For Pub - Principal Register |
| 2022-04-26 | Teas Response To Office Action Received |
| 2022-04-26 | Correspondence Received In Law Office |
| 2022-04-26 | Teas/Email Correspondence Entered |
| 2021-10-27 | Priority Action Written |
| 2021-10-27 | Priority Action E-Mailed |
| 2021-10-27 | Notification Of Priority Action E-Mailed |
| 2021-10-21 | Assigned To Examiner |
| 2021-06-22 | New Application Office Supplied Data Entered |
| 2021-03-23 | New Application Entered |
Goods & services by class
Class 42 Technology & SaaS
Research and development of pharmaceuticals, namely, small molecule therapies for the alteration of RNA splicing and expression, used in the treatment of cancers, neurological diseases, infectious diseases and other diseases using integrated and high-throughput screening technologies coupled with next-generation sequencing
First use anywhere 8 Apr 2024 · First use in commerce 8 Apr 2024
Owner details
See the official record for contact details. View official record →
Source & freshness
Source: the official United States trademark register. This record was last updated on 8 Apr 2025; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.